[Congressional Record Volume 163, Number 5 (Monday, January 9, 2017)]
[Senate]
[Page S157]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 25. Mr. FRANKEN submitted an amendment intended to be proposed by 
him to the concurrent resolution S. Con. Res. 3, setting forth the 
congressional budget for the United States Government for fiscal year 
2017 and setting forth the appropriate budgetary levels for fiscal 
years 2018 through 2026; which was ordered to lie on the table; as 
follows:

       At the end of title III, add the following:

     SEC. 3___. DEFICIT-NEUTRAL RESERVE FUND RELATING TO UNFAIR 
                   TAX BREAKS TO DRUG COMPANIES.

       The Chairman of the Committee on the Budget of the Senate 
     may revise the allocations of a committee or committees, 
     aggregates, and other appropriate levels in this resolution 
     for one or more bills, joint resolutions, amendments, 
     amendments between the Houses, motions, or conference reports 
     relating to the deduction for advertising and promotional 
     expenses for prescription drugs, which may include reducing 
     the cost of prescription drugs by disallowing the deduction 
     for direct-to-consumer advertising of prescription drugs, by 
     the amounts provided in such legislation for those purposes, 
     provided that such legislation would not increase the deficit 
     over either the period of the total of fiscal years 2017 
     through 2021 or the period of the total of fiscal years 2017 
     through 2026.
                                 ______